Table 8 Mortality in secondary bacteremia patients receiving C/T

Case series

 Hakki and Lewis et al., 2018 [26]

Case series

NR^a

P. aeruginosa: 100%

MDR infection: 100%

Defined as patients surviving

30 days

0% (0/3)

Randomized controlled trials (RCT)

 Kollef et al. et al., 2019 [30]

RCT

Nosocomial pneumonia

Pseudomonas^b: 17.4% (Not further specified), Enterobacter: 53.86%^c

–

–

28 days

52.0% (13/25)

Retrospective cohort studies

 Bosaeed et al., 2020 [13]

Retrospective cohort (single patient)

Complicated perianal abscesses

Pseudomonas: 100% (not further specified)

MDR infection: 100%

–

30 days

100% (1/1)

 Gallagher et al., 2018 [17]

Retrospective cohort

Mixed infections:

bone/ joint, intra-abdominal, pneumonia, wound, and UTI

Pseudomonas: 100% (not further specified)

MDR infection: 100%

–

–

36.8% (7/19)

 Haidar et al., 2017 [18]

Retrospective cohort

Pneumonia

P. aeruginosa: 100%

MDR infection: 100%^c

Defined as P. aeruginosa if the patient died with signs and symptoms of infection, microbiologic or histological evidence of an active P. aeruginosa infection, and

if other potential causes of death were reasonably excluded

30 days for patient 1

90 days for patient 2

0% (0/2)

 King et al., 2018 [11]

Retrospective cohort

Mixed infections:

Pneumonia (N = 8), UTI (N = 7), intra-abdominal (N = 4), wound (N = 1)

Pseudomonas: 100% (not further specified)

MDR infection: 100%

–

30 days

44.4% (8/18)^d,e,f

 Rodriguez-Nunez et al., 2019 [21]

Retrospective cohort

Lower respiratory tract infection

Pseudomonas: 100% (not further specified)

–^g

–

30 days

25.0% (1/4)